It took the brand manufacturers more than two years to build enough capacity for the FDA to declare the shortages over, which happened on December 19, 2024, for Eli Lillys tirzepatide products, and February 21, 2025, for Novo Nordisks semaglutide products
Receptor binding affinity, receptor residence time, and pharmacokinetic properties all influence real-world outcomes
Moreover, the recovery of adiponectin secretion observed in Retatrutide-treated mice is mechanistically relevant
If a person has too little GLP-1, this may lead to a person eating more during meals or snacking between meals
Potential problems include skin irritation, wasted money, and putting off proper treatment
Good value Reliable product at a more accessible price point